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Abstract
Background: Computerized decision support systems (CDSSs) are increasingly used to improve quality of care.
There is evidence for moderate to large effects from randomized controlled trials (RCTs), but evidence on their
effectiveness when implemented at a national level is lacking. In the Netherlands, the Dutch College of General
Practitioners (NHG) initiated their successful guideline program already 30 years ago. NHGDoc, a CDSS based on
these NHG guidelines, covering multiple disease areas for general practice, was developed in 2006 with the aim to
improve quality of primary care. In this paper, a protocol is presented to evaluate the uptake and effects of
NHGDoc.
Methods: A cluster RCT will be conducted among 120 general practices in the Netherlands. Eligible general
practices will be randomized to receive either the regular NHGDoc decision support modules (control arm) or the
regular modules plus an additional module on heart failure (intervention arm). The heart failure module consists of
patient-specific alerts concerning the treatment of patients with heart failure. The effect evaluation will focus on
performance indicators (e.g., prescription behavior) as well as on patient outcomes (e.g., hospital admissions)
relevant in the domain of heart failure. Additionally, a process evaluation will be conducted to gain insight into the
barriers and facilitators that affect the uptake and impact of NHGDoc.
Discussion: Results of this study will provide insight in the uptake and impact of a multiple-domain covering CDSS
for primary care implemented by a national guideline organization to improve the quality of primary care. Whereas
the trial focuses on a specific domain of care—heart failure—conclusions of this study will shed light on the
functioning of CDSSs covering multiple disease areas for primary care, particularly as this study also explores the
factors contributing to the system’s uptake and effectiveness.
Trial registration: Clinical trials NCT01773057
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Background
Clinical practice guidelines aim to improve quality of care,
but their implementation in practice remains a challenge.
Despite considerable efforts in improving guideline imple-
mentation, several reviews have shown that guidelines are
only moderately effective in changing clinical practice [1,2].
A study in the US showed that only about half of the pa-
tients received care as recommended in the guidelines [3].
Similarly, in other countries, adherence to the guidelines
among physicians is found to be suboptimal as well [4,5].
Computerized decision support systems (CDSSs) are
one of the tools that can be used to improve the uptake of
guidelines in practice. By linking characteristics of individ-
ual patients to a computerized medical knowledge base,
they can provide patient-specific recommendations to
healthcare providers during patient care [6]. To the extent
that CDSSs are guideline-driven, i.e., if the content is dir-
ectly derived from clinical practice guidelines, they have
the potential to increase physicians’ adherence to guide-
lines and ultimately lead to improved patient outcomes.
Whereas CDSSs are increasingly being used in various
healthcare settings, evidence is mainly retrieved from
small-scale academic-driven experiments among selected
groups of innovators. Definitive evidence on their effect-
iveness in large-scale practice-driven use of CDSSs re-
mains to be established. Some studies have shown that
CDSSs can improve medical practice, e.g., [6-9]. In a re-
cent series of six systematic reviews [10], it was found that
CDSSs improved the process of medical care in 52%–64%
of studies across all six reviews. However, only 15%–31%
of those reviews that evaluated patient outcomes showed
a positive impact on patients’ health [11-17].
Moreover, CDSSs seem to have added value as a tool
for improving quality of care when focusing on specific
behaviors (e.g., drug dosing) [6,7] within well-defined
areas of care. A large share of medical care, however, is
delivered by primary care practitioners (PCPs), particu-
larly in the Netherlands [18]. PCPs work in generic set-
tings and are confronted with a variety of diseases. This
setting necessitates CDSSs covering multiple disease
areas. Thus far, little is known on the effectiveness of
CDSSs in settings in which PCPs are exposed to various
alerts within multiple domains of care.
In the Netherlands, the Dutch College of GPs (NHG) ini-
tiated their successful guideline program already 30 years
ago [19]. In 2006, NHGDoc, a CDSS based on these NHG
guidelines and covering multiple disease areas for general
practice, was developed as a collaborative effort between
the Dutch College of GPs (NHG) [19] and ExpertDoc [20],
a private enterprise. The content of NHGDoc is directly
derived from the NHG guidelines—the national prevailing
guidelines for general practice. NHGDoc is gradually being
implemented at a national level and is currently—at the
onset of the trial—integrated into two out of eight
electronic health record systems (EHRSs) used in Dutch
general practice, covering about 25% of all general prac-
tices in the Netherlands.
The aim of the study outlined in this protocol is to evalu-
ate the uptake and effectiveness of the CDSS NHGDoc on
the quality of primary care in the Netherlands. More spe-
cifically, our study’s aims are as follows:
1. To assess the effects of the CDSS NHGDoc on
relevant performance indicators for the process of
medical care
2. To assess the effects of the CDSS NHGDoc on
patient outcomes
3. To gain insight into the determinants that affect the
uptake and impact of NHGDoc
Methods/design
Study design
A two arm-cluster (before and after) RCT will be con-
ducted with a follow-up period of 12 months. Rando-
mization will take place at a practice level, i.e., general
practices will be randomized to the control arm or the
intervention arm rather than individual PCPs. This will
be the preferred unit of allocation as the intervention
(i.e., the NHGDoc module on heart failure) can only be
implemented at the level of the practices. Moreover, this
is done to avoid possible contamination between PCPs
working within the same practice yet being allocated to
different study groups [21].
This study has been designed and will be reported in
accordance with the CONSORT statement [22,23] and
its extension regarding cluster RCTs [24] (see Additional
file 1).
Setting
The study will be conducted within the Dutch primary
care setting. In the Netherlands, there are approximately
5,000 general practices in which nearly 11,000 GPs are
delivering care [25]. Almost all GPs are members of the
Dutch College of General Practitioners (NHG). Since the
late 1980s, the NHG has produced over 100 national
clinical practice guidelines for general practice [19]. These
NHG guidelines cover the vast majority of conditions and
diseases frequently seen in general practice. Currently,
eight of these guidelines have been integrated into
NHGDoc, i.e., cardiovascular risk management, asthma/
COPD, diabetes mellitus type II, thyroid disorders, viral
hepatitis and other liver diseases, atrial fibrillation, and
subfertility.
Additional to GPs, approximately 3,000 practice nurses
(PNs) are delivering care in approximately 60% of the
Dutch general practices. They are mainly responsible for
regular checks of the chronically ill such as cardiovascu-
lar and asthma/COPD patients [26].
Lugtenberg et al. Implementation Science 2014, 9:145 Page 2 of 9
http://www.implementationscience.com/content/9/1/145
NHGDoc was developed in 2006 as a collaborative ef-
fort between the NHG [19] and ExpertDoc [20]. As the
NHG is the owner of the system and is an organization
highly appreciated among GPs, it was decided to intro-
duce the name ‘NHGDoc’ to the CDSS. NHGDoc is at
the time of recruiting practices for the study integrated
into two (MicroHIS X and Promedico-ASP) out of eight
EHRSs used in Dutch general practice. These two sys-
tems cover about 25% of all Dutch general practices.
Participants
All general practices in the Netherlands that use either
the EHRS MicroHIS X or Promedico-ASP and thus have
NHGDoc at their disposal, will be invited to participate
in the study (n = approximately 1,100). To invite general
practices to participate in the study, a comprehensive re-
cruitment plan will be executed. All general practices
will be approached by ordinary post mail signed by the
NHG as well as an email signed by the EHRS providers
(MicroHIS X and Promedico-ASP) and their user associ-
ations (Orego and Atlas). Additionally, announcements
about the evaluation study will be placed in several rele-
vant Dutch journals, websites, newsletters, and through
social media (i.e., Facebook, Twitter, and LinkedIn). In
all messages, reference will be made to the website of
the evaluation study (www.nhgdoc-evaluatie.nl) which
presents information about the study as well as an on-
line registration form for general practices. To enable
blinding of participants and contrast between groups,
the study is purposefully presented as a before-after
study without a concurrent control group, rather than as
a before-after RCT. Therefore, the participants will not
be aware of the fact that they will be allocated at random
to two different conditions.
In order to participate in the study, each general prac-
tice should fill out the online registration form. The ap-
plicant is asked to consent on behalf of all practice staff
(GPs and PNs) that could potentially use NHGDoc. This
is necessary as the intervention and data collection can
only be implemented at the level of the practices. We
will, however, be able to distinguish between different
users in analyzing the study results.
Intervention and comparisons
Control arm: regular NHGDoc decision support
General practices assigned to the control arm receive
the regular NHGDoc decision support. These practices
receive decision support with respect to all modules
(NHG guidelines) that—at the onset of the trial—have
been integrated into NHGDoc (see ‘Description of
NHGDoc and its regular modules (control arm)’
section).
Description of NHGDoc and its regular modules (control
arm)
NHGDoc is a CDSS integrated within the EHRS and based
on the NHG guidelines, the prevailing guidelines for gen-
eral practice in the Netherlands. It provides GPs and PNs
evidence-based and patient-specific advices during consult-
ation in terms of patient data registration, drug prescrip-
tion, and management.
At the time of the onset of the trial, NHGDoc covered
the following NHGDoc modules: cardiovascular risk
management, asthma/COPD, diabetes mellitus type II,
thyroid disorders, viral hepatitis and other liver diseases,
atrial fibrillation, and subfertility. For each NHG guide-
line, key recommendations have been selected based on
relevance of disease burden, room for improvement, and
possibility to translate or normalize the recommendation
into if-then rules. This selection of key recommendations
is approved by representative experts of the guideline
committees. Subsequently, the selected key recommenda-
tions are digitized into NHGDoc.
When the GP or PN opens a patient file in the EHRS,
anonymous patient and performance data are sent to the
NHGDoc server. The patient and performance data are
compared to the digitized guideline recommendations
and in the case of a discrepancy between current and ad-
vised care, an alert will be sent back to the GP or PN.
Intervention arm: regular modules plus additional module
on heart failure
General practices allocated to the intervention arm will
receive the same decision support modules as the con-
trol arm (see ‘Description of NHGDoc and its regular
modules (control arm)’ section), extended with the
NHGDoc module on heart failure, which will be acti-
vated at the onset of the trial (see ‘Basic elements/key
recommendations of the NHGDoc module on heart fail-
ure (intervention arm)’ section). The reason we chose
heart failure to be the subject of the trial was first of all
of pragmatic nature; heart failure was one of the few
modules that were to be implemented into NHGDoc in
the year of the onset of the trial. In addition, we chose
heart failure as it is a relatively common condition for
which relatively large improvements (in terms of in-
creasing or decreasing mortality and morbidity) are to
be expected if healthcare providers adhere to the treat-
ment guidelines, compared to other conditions [27-31].
Basic elements/key recommendations of the NHGDoc
module on heart failure (intervention arm)
The NHGDoc module on heart failure is directly derived
from the NHG guideline on heart failure [32]. It consists
of three types of alerts:
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1. Alerts on heart failure in terms of registering the
following patient data:
– clearance of creatinine;
– (serum) creatinine;
– (serum) potassium;
– (serum) sodium;
– patient weight;
– heart (frequency);
– blood pressure (systolic and diastolic).
2. Alerts on heart failure in terms of prescribing (or
adjusting the dose of ) the following drugs:
– (lis)diuretics;
– ACE-inhibitor;
– AII antagonist;
– potassium suppletion;
– beta-blocker;
– aldosterone antagonist;
– digoxin.
For example: Stop prescribing ACE-inhibitor be-
cause of the reduced clearance of creatinine and the
increased serum potassium and check these values.
3. Alerts on heart failure in terms of (paying attention
to) the following management aspects such as:
– stop prescribing medication such as calcium
antagonist, thiazolidinedione, disopyramide or a
combination of ACE-inhibitor and AII
antagonists;
– consider adjusting the dosage of medication when
hypertension is increasing;
– consider use of NSAID;
– consider weight policy, e.g., discuss weight
reduction and consider increasing the dosage of
diureticum if weight increases with two kilogram
or more within a short period of time;
– consider temporary restriction of fluids;
– advice to give up smoking;
– consider sleeping research and;
– consider referral to a cardiologist or nephrologist.
Study measures
Outcomes
To select outcome measures for our evaluation study,
we first identified previously validated indicators for
heart failure [33]. Subsequently, we consulted an expert
panel of general practitioners as well as specialists in
the area of heart failure to select the outcome measures
that are clinically most relevant for our study and that
are suitable for quantitative evaluation. Outcomes will
be measured during the year before the start of the
intervention (baseline) and in the first year following
the start of the intervention (follow-up). This resulted
in the following primary and secondary outcome
measures:
Primary outcome measures (per practice, per year):
➢ Prescribing of ACE-inhibitors/angiotensin II
Percentage of consultations in which a patient with
heart failure was prescribed ACE-inhibitors/angiotensin II.
➢ Prescribing of beta-blockers
Percentage of consultations in which a patient with
heart failure was prescribed beta-blockers.
➢ Prescribing of diuretics
Percentage of consultations in which a patient with
heart failure was prescribed diuretics.
Secondary outcome measures:
➢ Use of the system NHGDoc
Number of requests sent and alerts received for all
patients; number of requests sent and alerts received
for heart failure patients; percentage of opened alerts
compared to the number received alerts; percentage of
opened alerts compared to the number received alerts
for heart failure patients; mean delivery time for an
alert; number of practices that switched any module
off; for each module, the number/percentage of prac-
tices with at least one user who switched the module
off; and number of practices with at least one user who
switched the module heart failure off (intervention
group only).
➢ Patient data registration
Percentage of consultations in which for a patient
with heart failure, relevant patient data have been
registered: clearance of creatinine (<12 mnd); (serum)
creatinine (<12 mnd); (serum) potassium (<12 mnd);
(serum) sodium (<12 mnd); patient weight (<6 mnd);
heart (frequency) (<6 mnd); blood pressure (systolic and
diastolic) (<6 mnd).
➢ Hospital admissions
Number of hospital admissions of patients with heart
failure.
➢ All cause mortality
Number of patients with heart failure that died in the
hospital.
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Sample size
The minimum required number of general practices was
based on the two main primary outcome measures: pre-
scribing of ACE-inhibitors/angiotensin II and prescrib-
ing of beta-blockers. The anticipated improvement was
based on literature [27,28] as well as on consultation of
experts in the field (ACE-inhibitor change from 63%–
69%; beta-blockers from 59%–65%). As for beta-
blockers, to detect this difference, we will need at least
122 general practices completing the trial with 80%
power at a type I error risk (α) of 5%, taking an esti-
mated intra-cluster correlation of 0.1 into account [34].
With this number of practices, the study will also be able
to detect the difference for prescribing of ACE-inhibitors
(minimum number of practices =116). We do not, how-
ever, expect to be able to detect an effect on hospital ad-
missions and hospital mortality with this number of
practices.
Randomization
Eligible general practices will be randomly allocated to
either the intervention arm or the control arm, stratified
by type of EHRS (MicroHIS X or Promedico-ASP) (see
Figure 1). Practices will be the unit of randomization.
Before randomization, the practices will be clustered at
the level of practice addresses (practice AGB code and
zip code) to avoid GPs and practices that are located within
the same building being designated to different study
groups. Randomization will be central and computer-
generated, executed by an independent person (one of the
members of the research team without any COI towards
allocation). Dedicated software will be used to generate a
randomization scheme with an equal number of control
and intervention practices.
Blinding
General practices and the staff working within these prac-
tices will be blinded to group allocation. They will not be
informed about being allocated to either the intervention
group or the control group (see ‘Participants’ section). They
are even unaware of participating in an intervention trial
with a concurrent control group. However, as the interven-
tion arm will, at the onset of the trial, receive decision
support on heart failure (directly available to all interven-
tion practices at one preset moment in time) without the
usual communication about the implementation of a new
module, these practices may suspect heart failure to be the
subject/topic of the trial. Therefore, the extent to which the
blinding was really successful will be checked in a survey,
which is part of the process evaluation of the trial.
Patients will also be blinded to group allocation as they
are not aware and are not likely to become aware of the
trial (design). Given the fact that patients are not being
exposed to experimental interventions and that all patient
data used in our evaluation study are anonymized, we are
not obliged to inform patients about the use of these data,
nor do we have to offer them an opt-out option. And
finally, researchers will also be blinded to the group alloca-
tion as the randomization variables will be labeled with
the letters A and B (rather than I and C) for the control
and intervention group by a third independent researcher.
Baseline measurement
Assessment of general practices for eligibility
Randomization
Stratification*
Allocation to intervention arm
(regular modules plus module on Heart Failure)
Follow-up measurement
(process and effect evaluation)
Allocation to control arm
(regular NHGDoc modules)
Follow-up measurement
(process and effect evaluation)
Figure 1 Study flow diagram. *Stratification will be based on the type of EHRS.
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Data collection
To investigate the effectiveness of NHGDoc, data will be
collected from two sources: the NHGDoc server and
Dutch Hospital Data.
NHGDoc server
For the largest part of this study, existing data collection
methods from the NHGDoc alert service that have been
developed by ExpertDoc to generate CDSS alerts for
NHGDoc will be used. These are all automated data
extractions from electronic patient records available in
the EHRS. The NHGDoc alert service only uses anon-
ymized patient data, and data are only streamed and not
stored. For this evaluation study, however, it is necessary
to save the anonymous data for the follow-up period of
a year. Therefore, ExpertDoc, the company that manages
the data, will send the NHGDoc data on a monthly
basis, secured with a log in code, to IQ healthcare.
NHGDoc data include all alerts, and the anonymous pa-
tient data that generate the alerts.
Dutch Hospital Data
To be able to detect the effects of NHGDoc on patient
outcomes, we also use data from Dutch Hospital Data
(DHD), a foundation that collects and manages data of
Dutch hospitals. Based on the practice codes (practice
AGB codes) of the participating practices in both arms,
DHD selects relevant data with respect to hospital
admissions and mortality of patients that are registered
with ICD-code I50 of the ICD 10 and sends them, after
anonymizing the dataset, to IQ healthcare.
Analysis
To assess the effects of NHGDoc in terms of improving
the quality of primary care, the scores on outcomes mea-
sures during the follow-up period will be compared
between both study arms adjusted for baseline findings.
To take into account potential clustering of effects
within practices, multilevel models will be used.
The primary outcome measures are the percentage of
consultations in which a patient with heart failure is pre-
scribed 1. ACE-inhibitors/angiotensin II, 2. beta-blockers,
and 3. diuretics. To assess the effects of NHGDoc on each
of these variables, multilevel linear regression analysis will
be performed. To assess the effects of NHGDoc on mor-
tality, logistic regression analysis will be used, adjusting
for severity of illness at hospital admission and comorbid-
ity as measured by the Charlson Comorbidity Index. Both
patient-level and practice-level intercept estimates will be
used to account for potential correlation of measurements
within patients and within general practices. We do not
use the provider level estimates in our analyses as the
difference between number of practices and providers
will be too small due to solo practices. Moreover,
patients may visit different GPs within the same prac-
tice during the year making this distinction less rele-
vant as well.
Process evaluation
Aside from the effect evaluation, a process evaluation will
be conducted to gain insight into the barriers and facilita-
tors that affect the system’s uptake and impact [35]. The
actual exposure of the PCPs to the intervention as well as
their experience with the intervention may have affected
the results of the study and will be investigated. Results of
the process evaluation will be used to improve (the imple-
mentation of) NHGDoc.
Data will be collected among participants in the inter-
vention and control arm in three different ways. First,
some variables measuring exposure to the intervention
(e.g., not functioning of the server, deliberately turning
off the heart failure module or particular areas within
this module) will be collected by the NHGDoc server.
Second, three focus groups will be conducted among
NHGDoc users (eight to ten GPs and PNs per group) to
gain insight into their experiences with CDSSs in general
and NHGDoc in particular. In each focus group, barriers
and facilitators will be discussed using a topic list. Par-
ticipants will be recruited by sending a direct email and
reminders to all participating practices. If necessary,
additional announcements will be placed on relevant
websites and through social media (i.e., Facebook, Twitter,
and LinkedIn).
And finally, an electronic questionnaire will be sent to all
participating practices at the end of the study period to
triangulate the findings of the study. Aside from quantita-
tively assessing the perceived barriers and facilitators to
using CDSSs in general and NHGDoc in particular, atten-
tion will be paid to the exposure to and experiences with
the specific heart failure module. Also, the intended ‘blind-
ing’ in terms of the content of the intervention as well as
the group allocation will be checked among participants.
Exposure to and experiences with NHGDoc will be an-
alyzed descriptively. Data from the focus groups will be
audiotaped, verbatim transcribed, and independently an-
alyzed by two researchers using content analysis with
the software program AtlasTi7.0.
Ethical considerations
In the Netherlands, studies involving human subjects
need to undergo a medical ethics review if they are sub-
ject to the Medical Research Involving Human Subjects
Act (WMO). The study protocol was assessed by the
Medical Ethics Committee (CMO) (of district Nijmegen/
Radboud) and declared that no further ethical approval
was required.
Moreover, the Dutch College of General Practitioners
(NHG) set up a privacy college for the use of data from
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NHGDoc in order to monitor whether all data related to
NHGDoc are used appropriately. Therefore, the study
protocol of our evaluation study was checked and
approved by this college. Also, the members from the
college have the option throughout the trial to check on
whether the data were encrypted and delivered as agreed
on in the protocol.
Trial status
At the time of manuscript submission, the trial is closed to
recruitment and follow-up. No data cleaning or analysis has
been executed prior to the submission of this manuscript.
Discussion
This paper describes the protocol of a cluster RCT,
which aims to evaluate the effectiveness of a multiple-
domain covering CDSS for primary care implemented
by a national organization. By means of a large-scale 1-
year trial, it will be investigated whether providing
guideline-driven and patient-specific advices to health-
care providers during consultation leads to improved
process of medical care and ultimately to improved pa-
tient outcomes. Additionally, insight will be gained into
the barriers and facilitators perceived by users that may
affect NHGDoc’s uptake and impact.
The effectiveness of CDSSs in primary care has been
evaluated in previous studies [6-17]. However, the CDSS
being subject of this trial exhibits some unique features.
First, NHGDoc is a guideline-driven CDSS for primary
care, which is being implemented by a national organi
zation. Whereas most CDSSs incorporate evidence-
based recommendations, in a few of them, the whole
content is directly derived from a set of national prevail-
ing clinical practice guidelines developed by a national
independent and respected organization. Moreover, the
system NHGDoc is also owned and implemented by this
independent professional organization. A CDSS such as
NHGDoc that is owned and implemented by an inde-
pendent professional national organization might be
more effective compared to CDSSs for which this link is
not established.
Another distinguishing feature of NHGDoc is its focus
on the generic setting of primary care. Most CDSSs have
been developed to target specific behaviors (e.g., pre-
ventive measures such as vaccinations, appropriate drug
dosing) within well-defined areas of care (e.g., intensive
care unit). NHGDoc is developed for a generic setting
and integrates multiple alerts within multiple domains of
care or disease areas. Although CDSSs have proven to
be successful in focusing on specific behaviors within
well-defined areas of care, very little is known [36,37] on
how systems designed for and used in a generic primary
care setting will function. This trial will shed some light
on this issue.
Although NHGDoc is a multiple-domain covering
CDSS, the design of the study does not allow us to dif-
ferentiate in the effects between the various domains of
care. The intervention in our trial consists solely of deci-
sion support in the area of heart failure. Nevertheless,
our study does provide insight into the extent that deci-
sion support on heart failure is effective in a setting in
which decision support is provided for several domains
of care. Moreover, the process evaluation in our study
will also provide insight in terms of the uptake and
effectiveness of decision support as part of a multiple
domain-covering CDSSs as well as its contributing/
factors.
A limitation of our study design is that we do not have
a ‘real’ control group, consisting of healthcare providers
not using NHGDoc at all. Although the control arm
does not receive decision support in the area of heart
failure, it does receive decision support with respect to
the regular NHGDoc modules that had already been
implemented at the onset of the trial. This may suggest
a selection bias with only GPs and PNs with a positive
attitude towards CDSSs participating in the trial. How-
ever, both the control and intervention arm consist of
general practices that have NHGDoc at their disposal
because it is integrated into their EHRS, rather than that
they have deliberately chosen for it. As a consequence,
it is unlikely that only highly motivated GPs and PNs
using NHGDoc frequently participate in our study.
Moreover, if there is any bias in terms of motivation
among participating GPs, we expect it to be equally dis-
tributed between the intervention and control arm, as a
result of the randomization process of the trial.
This study will shed light on the uptake and effectiveness
of CDSSs covering multiple disease areas in primary care,
which is owned and implemented by a national guideline
organization. By also exploring factors contributing to the
system’s uptake and effectiveness, insight will be provided
in how such systems should be designed and implemented
in order to function well in a generic primary care setting.
Results will not only be of interest to developers and
implementers of CDSSs but also to guideline implementers
using CDSSs to improve the uptake of guidelines and
ultimately patient outcomes in primary care.
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